Cancer Clinical Trial
Official title:
Evaluation of the Efficacy of Low-dose Acetylsalicylic Acid on Diarrhea Induced by Anti-cancer Targeted Therapies.
The mechanisms of action of the side effects associated with targeted therapies are still
poorly understood. He was found in patients treated with gefitinib, increased levels of
thromboxane B2 and P-selectin Thromboxane B2 is the result of the hydrolysis of thromboxane
A2, which is itself obtained from Prostaglandin H2 under the action of the thromboxane
synthetase. The thromboxane A2 is produced by platelets and the active pro-thrombotic
properties as follows: stimulation of platelets and activation of other increased platelet
aggregation.
The selectins are cell adhesion proteins with a role in the adhesion phenomena. P-selectin
is expressed by platelets and endothelial cells.
The demonstration of increased plasma levels of thromboxane B2 and P-selectin leaves suggest
a role of platelet activation in the occurrence of side effects associated with targeted
therapies.
Kanazawa's study was conducted in 39 Japanese patients, trying to assess the value of
low-dose acetylsalicylic acid or 100mg per day, that is to say, anti-aggrégantes doses, the
occurrence rash and diarrhea induced by gefitinib.
In this study, the group of patients treated with acetylsalicylic acid presented a lower
rate of side effects significantly, 58.3% versus 77.8%. The frequency of diarrhea was 18.5%
(or 5 patients) in the standard group versus 0% in the group with acetylsalicylic acid.
Similarly, it was found a reduction in the occurrence of skin rash, 33.3% or 4 patients in
the acetylsalicylic acid group versus 74.1% s, 20 patients in the standard group. Finally,
in this study, it was not revealed significant differences in terms of response to treatment
with gefitinib (37% in the standard group versus 33% in the group treated with aspirin
patient) It does not exist in our knowledge of prospective data evaluating the effect of
acetylsalicylic acid on the reduction of side effects associated with targeted in a
population of patients of Caucasian-type treatment.
n/a
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05346796 -
Survivorship Plan HEalth REcord (SPHERE) Implementation Trial
|
N/A | |
| Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
| Completed |
NCT04867850 -
Effect of Behavioral Nudges on Serious Illness Conversation Documentation
|
N/A | |
| Enrolling by invitation |
NCT04086251 -
Remote Electronic Patient Monitoring in Oncology Patients
|
N/A | |
| Completed |
NCT01285037 -
A Study of LY2801653 in Advanced Cancer
|
Phase 1 | |
| Completed |
NCT00680992 -
Study of Denosumab in Subjects With Giant Cell Tumor of Bone
|
Phase 2 | |
| Completed |
NCT00062842 -
Study of Irinotecan on a Weekly Schedule in Children
|
Phase 1 | |
| Active, not recruiting |
NCT04548063 -
Consent Forms in Cancer Research: Examining the Effect of Length on Readability
|
N/A | |
| Completed |
NCT04337203 -
Shared Healthcare Actions and Reflections Electronic Systems in Survivorship
|
N/A | |
| Recruiting |
NCT04349293 -
Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways
|
N/A | |
| Terminated |
NCT02866851 -
Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy
|
N/A | |
| Active, not recruiting |
NCT05304988 -
Development and Validation of the EFT for Adolescents With Cancer
|
||
| Completed |
NCT00340522 -
Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
|
||
| Recruiting |
NCT04843891 -
Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis.
|
Phase 1 | |
| Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
| Completed |
NCT03167372 -
Pilot Comparison of N-of-1 Trials of Light Therapy
|
N/A | |
| Completed |
NCT03109041 -
Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source
|
Phase 1 | |
| Terminated |
NCT01441115 -
ECI301 and Radiation for Advanced or Metastatic Cancer
|
Phase 1 | |
| Recruiting |
NCT06206785 -
Resting Energy Expenditure in Palliative Cancer Patients
|
||
| Recruiting |
NCT05318196 -
Molecular Prediction of Development, Progression or Complications of Kidney, Immune or Transplantation-related Diseases
|